238 related articles for article (PubMed ID: 15722457)
1. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.
Pedemonte N; Sonawane ND; Taddei A; Hu J; Zegarra-Moran O; Suen YF; Robins LI; Dicus CW; Willenbring D; Nantz MH; Kurth MJ; Galietta LJ; Verkman AS
Mol Pharmacol; 2005 May; 67(5):1797-807. PubMed ID: 15722457
[TBL] [Abstract][Full Text] [Related]
2. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating.
Yang H; Shelat AA; Guy RK; Gopinath VS; Ma T; Du K; Lukacs GL; Taddei A; Folli C; Pedemonte N; Galietta LJ; Verkman AS
J Biol Chem; 2003 Sep; 278(37):35079-85. PubMed ID: 12832418
[TBL] [Abstract][Full Text] [Related]
3. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.
Caputo A; Hinzpeter A; Caci E; Pedemonte N; Arous N; Di Duca M; Zegarra-Moran O; Fanen P; Galietta LJ
J Pharmacol Exp Ther; 2009 Sep; 330(3):783-91. PubMed ID: 19491324
[TBL] [Abstract][Full Text] [Related]
4. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
[TBL] [Abstract][Full Text] [Related]
5. Sulfamoyl-4-oxoquinoline-3-carboxamides: novel potentiators of defective DeltaF508-cystic fibrosis transmembrane conductance regulator chloride channel gating.
Suen YF; Robins L; Yang B; Verkman AS; Nantz MH; Kurth MJ
Bioorg Med Chem Lett; 2006 Feb; 16(3):537-40. PubMed ID: 16288863
[TBL] [Abstract][Full Text] [Related]
6. A novel natural product compound enhances cAMP-regulated chloride conductance of cells expressing CFTR[delta]F508.
deCarvalho AC; Ndi CP; Tsopmo A; Tane P; Ayafor J; Connolly JD; Teem JL
Mol Med; 2002 Feb; 8(2):75-87. PubMed ID: 12080183
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel.
Cai Z; Taddei A; Sheppard DN
J Biol Chem; 2006 Jan; 281(4):1970-7. PubMed ID: 16311240
[TBL] [Abstract][Full Text] [Related]
8. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating.
Xu LN; Na WL; Liu X; Hou SG; Lin S; Yang H; Ma TH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):878-83. PubMed ID: 18430055
[TBL] [Abstract][Full Text] [Related]
9. [Butyl-p-hydroxybenzoate stimulates cystic fibrosis transmembrane conductance regulator Cl- transport].
Ge H; Hou TT; Sun JJ; Yang H
Yao Xue Xue Bao; 2009 Jan; 44(1):32-7. PubMed ID: 19350818
[TBL] [Abstract][Full Text] [Related]
10. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.
Dalemans W; Barbry P; Champigny G; Jallat S; Dott K; Dreyer D; Crystal RG; Pavirani A; Lecocq JP; Lazdunski M
Nature; 1991 Dec 19-26; 354(6354):526-8. PubMed ID: 1722027
[TBL] [Abstract][Full Text] [Related]
11. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
Verkman AS; Lukacs GL; Galietta LJ
Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
[TBL] [Abstract][Full Text] [Related]
12. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects.
Bompadre SG; Sohma Y; Li M; Hwang TC
J Gen Physiol; 2007 Apr; 129(4):285-98. PubMed ID: 17353351
[TBL] [Abstract][Full Text] [Related]
13. Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker.
Taddei A; Folli C; Zegarra-Moran O; Fanen P; Verkman AS; Galietta LJ
FEBS Lett; 2004 Jan; 558(1-3):52-6. PubMed ID: 14759515
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
[TBL] [Abstract][Full Text] [Related]
15. Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines.
Haws CM; Nepomuceno IB; Krouse ME; Wakelee H; Law T; Xia Y; Nguyen H; Wine JJ
Am J Physiol; 1996 May; 270(5 Pt 1):C1544-55. PubMed ID: 8967457
[TBL] [Abstract][Full Text] [Related]
16. A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.
French PJ; van Doorninck JH; Peters RH; Verbeek E; Ameen NA; Marino CR; de Jonge HR; Bijman J; Scholte BJ
J Clin Invest; 1996 Sep; 98(6):1304-12. PubMed ID: 8823295
[TBL] [Abstract][Full Text] [Related]
17. Mechanosensitivity of wild-type and G551D cystic fibrosis transmembrane conductance regulator (CFTR) controls regulatory volume decrease in simple epithelia.
Xie C; Cao X; Chen X; Wang D; Zhang WK; Sun Y; Hu W; Zhou Z; Wang Y; Huang P
FASEB J; 2016 Apr; 30(4):1579-89. PubMed ID: 26683699
[TBL] [Abstract][Full Text] [Related]
18. The glycine residues G551 and G1349 within the ATP-binding cassette signature motifs play critical roles in the activation and inhibition of cystic fibrosis transmembrane conductance regulator channels by phloxine B.
Melin P; Norez C; Callebaut I; Becq F
J Membr Biol; 2005 Dec; 208(3):203-12. PubMed ID: 16604470
[TBL] [Abstract][Full Text] [Related]
19. Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist.
Namkung W; Park J; Seo Y; Verkman AS
Mol Pharmacol; 2013 Sep; 84(3):384-92. PubMed ID: 23788656
[TBL] [Abstract][Full Text] [Related]
20. Influence of cell background on pharmacological rescue of mutant CFTR.
Pedemonte N; Tomati V; Sondo E; Galietta LJ
Am J Physiol Cell Physiol; 2010 Apr; 298(4):C866-74. PubMed ID: 20053923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
